FDA Oncology Announcements

Anti-PD-1 × Lymphoid × Clear all

4 Announcements

FDA approves nivolumab with chemotherapy for previously untreated Hodgkin lymphoma

Drugs: Opdivo (nivolumab) · Anti-PD-1 antibody, doxorubicin · Anthracycline
Condition: Lymphoid

FDA extends approval of pembrolizumab for classical Hodgkin lymphoma

Trial: MK-3475-204
Drug: KEYTRUDA (pembrolizumab) · Anti-PD-1 antibody
Condition: Lymphoid

FDA approves pembrolizumab for treatment of relapsed or refractory PMBCL

Trial: MK-3475-170
Drug: Keytruda (pembrolizumab) · Anti-PD-1 antibody
Condition: Lymphoid

Nivolumab (Opdivo) for Hodgkin Lymphoma

Drug: Opdivo (nivolumab) · Anti-PD-1 antibody
Condition: Lymphoid